TROP2-targeting MPC

About Catena Biosciences

Catena Biosciences is a private, pre-clinical biotech pioneering a novel protein conjugation platform to overcome key limitations of current antibody-drug conjugates (ADCs). Its core innovation is the CysTyr platform, which utilizes a proprietary enzyme to form a stable C-Y Bond between natural amino acids, enabling the attachment of multiple, diverse payloads (e.g., toxins, nucleic acids, cytokines) to a single antibody with precise control. With an early pipeline focused on dual-payload ADCs for solid tumors like TROP2-expressing cancers, Catena aims to demonstrate superior efficacy and reduced off-target toxicity compared to standard ADCs. The company is at an early stage, building its leadership team and advancing its platform toward proof-of-concept in vivo data.

Therapeutic Areas